The emergence of the Cicada COVID-19 variant has raised significant concern globally, particularly as it has now been detected in India. This variant, classified as BA.3.2, is an offshoot of the Omicron family tree, indicating it is not a completely new threat but rather a continuation of the ongoing battle against COVID-19.
First spotted in South Africa in November 2024, the Cicada variant carries around 75 mutations, with over 50 of these located in the spike protein. This extensive mutation profile has led to increased scrutiny from health authorities worldwide.
Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash. While these symptoms are concerning, it is important to note that the Cicada variant is not confirmed to cause more severe illness than previous variants.
As of now, the variant has been detected in 22 countries, including India, which has prompted health officials to monitor its spread closely. The first confirmed case of the Cicada variant in the United States was reported in June 2025, and by January 2026, three patients had been confirmed, all of whom recovered.
Dr. Robert Hopkins Jr. has stated, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This highlights the uncertainty surrounding the variant’s potential impact on public health.
The Centers for Disease Control and Prevention (CDC) emphasized the importance of monitoring the spread of BA.3.2, noting that it provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from previous infections or vaccinations.
Details remain unconfirmed regarding the real-world data on the severity of illness caused by the Cicada variant. As health authorities continue to gather information, the situation remains fluid.
In conclusion, the detection of the Cicada variant in India underscores the ongoing challenges posed by COVID-19 and the need for vigilance in monitoring and responding to new variants as they emerge.
